Hudson Robotics' Varyscreen ADME-Tox integrated workstation speeds up the accurate profiling of the absorption, distribution, metabolism and excretion (ADME) properties of drug molecules.
Varyscreen ADME-Tox lets researchers perform screens starting with just a single plate, yielding a complete profile more quickly and at a lower cost.
Alan Katz, chief scientific officer of Hudson Robotics, said: 'The Varyscreen ADME-Tox system will perform ADME profiling up to three times faster than current processes.
'It performs the variety of assays required, yet demands less intervention by the user and less compound while delivering quality results.' The basic Varyscreen ADME system contains everything needed to support biochemical assays that measure the physicochemical properties of a drug molecule (that is to say solubility, lipophilicity, pKa and protein binding).
It supports Pampa and Caco 2 permeability assays and can measure a drug's affinity towards key toxilogical targets such as HERG and various CYP metabolic enzymes.
Controlled by Hudson Robotics's Softlinx scheduling software, Varyscreen ADME-Tox comes with sample protocols for each of the included ADME/toxicity methods.
The protocols are easily modified to meet user requirements and more assays can be added to further customise follow-up screening efforts.
Varyscreen ADME-Tox includes a multi-mode reader that supports the wide range of protocols and also runs primary and secondary screens.
This enables ADME/tox profiling to be carried out automatically on hits found in the assays.
